Bracco Diagnostics

December 2019: LUMASON is now approved for pediatric patients with suboptimal echocardiograms.

September 2019: Test your skills at GreatSonographer.com, an interactive and educational program that illustrates the value of ultrasound contrast.

January 2017: The FDA removes the contraindication for use of Bracco Diagnostics Inc.’s LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use, in patients with cardiac shunts

March 2016: LUMASON is now FDA approved for use in ultrasonography of the liver

Please read the press release and prescribing information for more information.

Lumason Formulary Kit: includes Lumason Product Monograph, Safety Data Sheet, FDA Approval Letter, and Prescribing Information

Lumason Brochure: overview of products (Updated Brochure coming soon)

2019 LUMASON® Reimbursement Guide

 

November 2015: Lumason® approved for reimbursement by CMS
To learn more about how to code Bracco’s new ultrasound contrast agent, visit here and read the press release here.

GE Healthcare

FDA removes hypersensitivity to blood and blood products contraindication for Optison

GE Healthcare Receives FDA Approval for Change in Contraindications in Prescribing Information for Optison™

GE ultrasound contrast agent Optison gets FDA OK for label change

Optison Dosing, Handling, & Administration Training Video

Quick Reference Guide for Using Optison

Additional Optison resources including case studies, educational programs and a reimbursement guide

Optison Prescribing Information

Lantheus Medical Imaging

DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
Lantheus Medical Imaging, Inc.

DEFINITY® Prescribing Information

On-Demand Webinars

Clinical Case Studies

Dosing and Administration

Image Optimization

FAQs

Reimbursement